<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[fda Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/fda.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to fda]]></description>
	<s:counts start="0" returned="20" found="11371" />
	<language>en-us</language>
	<item>
		<title><![CDATA[How Much To Extend Life? Allos Therapeutics Says $30,000 per Month]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005799/how-much-to-extend-life-allos-therapeutics-says-30000-per-month/]]></link>
		<description><![CDATA[Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma rrPTCL.  A successful rollout is not guaranteed, however, as Folotyn is also one of the most expensive chemotherapeutic agents on the market --...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 14 Dec 2009 09:01:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/rollout.html"><![CDATA[Rollout]]></category>
		<category domain="http://resources.bnet.com/topic/allos+therapeutics.html"><![CDATA[Allos Therapeutics]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/real+estate.html"><![CDATA[Real Estate]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Dislikes Canadian Drugs; Is OK With Chinese Drugs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005764/fda-dislikes-canadian-drugs-is-ok-with-chinese-drugs/]]></link>
		<description><![CDATA[FDA Commissioner Margaret Hamburg said that allowing reimportation of drugs from Canada raised significant safety questions, in a letter to to Republican Sen. Sam Brownback of Kansas, according to the Wall Street Journal. The story notes that the drug industry lobby group PhRMA also opposes reimportation and has been fighting...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 10 Dec 2009 08:37:39 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Would complete disclosure cure the NDA-rejection rash?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/complete-disclosure-cure-nda-rejection/23339/]]></link>
		<description><![CDATA[ John Jenkins, the head of the FDA's Office of New Drugs, has the perfect cure for a chronic rash of poorly conceived new drug applications: Sunshine. And plenty of it, according to a piece in  The RPM Report . Jenkins suggests that the agency's complete response letters should...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 10 Dec 2009 08:08:42 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/application.html"><![CDATA[application]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+office.html"><![CDATA[Microsoft Office]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/response+letter.html"><![CDATA[response letter]]></category>
	</item>
	<item>
		<title><![CDATA[GAO: Post-Vioxx, still no safety changes at FDA]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/gao-post-vioxx-safety-fda/23215/]]></link>
		<description><![CDATA[Three years after the Vioxx safety debacle, the FDA has yet to improve its drug safety oversight, according to Government Accountability Office findings. Vioxx was pulled from the market in 2004 after the drug was linked to an increased risk of heart attack and stroke. Two years later, the GAO, Institute...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 09 Dec 2009 09:58:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/microsoft+office.html"><![CDATA[Microsoft Office]]></category>
		<category domain="http://resources.bnet.com/topic/general+accounting+office.html"><![CDATA[General Accounting Office]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
	</item>
	<item>
		<title><![CDATA[Dendreon's New Stock Offering Takes Advantage of Provenge Decision Uncertainty]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005737/dendreons-new-stock-offering-takes-advantage-of-provenge-decision-uncertainty/]]></link>
		<description><![CDATA[Dendreon DNDN is taking advantage of the period of uncertainty before the FDA renders a May 1, 2010, decision on its Provenge prostate cancer treatment by raising money from a new stock sale. Dendreon shares fell today after the company announced it would dilute its 115.94 million outstanding shares with...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 09 Dec 2009 09:34:27 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[Investor]]></category>
		<category domain="http://resources.bnet.com/topic/dendreon.html"><![CDATA[Dendreon]]></category>
		<category domain="http://resources.bnet.com/topic/provenge.html"><![CDATA[Provenge]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Big Pharma's Facebook Fail]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005698/big-pharmas-facebook-fail/]]></link>
		<description><![CDATA[UCB Pharma (UCB.BR) has an Epilepsy Facebook page that doesn't mention it's published by UCB. And AstraZeneca AZN has a page for Nexium that does not let visitors post messages on its Wall. Adweek revisits the long-established phenom of drug companies not liking social media in case patients start telling...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 07 Dec 2009 12:57:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/facebook.html"><![CDATA[Facebook]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/social+media.html"><![CDATA[Social Media]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/web+2.0.html"><![CDATA[Web 2.0]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005680/shires-daytrana-patch-recall-is-8th-so-far-time-to-pull-the-plug/]]></link>
		<description><![CDATA[Shire SHPGY has voluntarily recalled the Daytrana ADHD patch citing problems with patients removing the liner on the back. It is not a safety issue, the company says. Daytrana is for children with ADHD; it is the only patch product to treat the condition. "Sudden death" is one of the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 07 Dec 2009 08:02:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/recall.html"><![CDATA[Recall]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/patch+management.html"><![CDATA[Patch Management]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/daytrana+adhd.html"><![CDATA[Daytrana ADHD]]></category>
		<category domain="http://resources.bnet.com/topic/noven.html"><![CDATA[Noven]]></category>
		<category domain="http://resources.bnet.com/topic/wilco.html"><![CDATA[Wilco]]></category>
		<category domain="http://resources.bnet.com/topic/patches.html"><![CDATA[Patches]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[FDA Has Only 2 Inspectors Watching Drug Factories in China]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005667/fda-has-only-2-inspectors-watching-drug-factories-in-china/]]></link>
		<description><![CDATA[The FDA has only two inspectors for medical products in China, the country to which much of the drug industry is moving its manufacturing and R&D facilities. The FDA confirmed the number at the request of BNET, following reports that Pfizer PFE, AstraZeneca AZN, Eli Lilly LLY and Novartis NVS...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 04 Dec 2009 12:14:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Abbott drug safety in FDA spotlight]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/abbott-drug-safety-fda-spotlight/22758/]]></link>
		<description><![CDATA[Abbott Laboratories gets a one-two safety punch today. First, the FDA issued a reminder warning about birth defects in babies born to pregnant women who take Depakote, the epilepsy drug that's also used in bipolar disorder and against maladies such as migraines. The drug and related versions, such as the...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 04 Dec 2009 08:58:48 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT</category>
	</item>
	<item>
		<title><![CDATA[iPhone App Offers Product Recall Information]]></title>
		<link><![CDATA[http://industry.bnet.com/food/news-analysis/iphone-app-offers-product-recall/22677/]]></link>
		<description><![CDATA[NEW YORK ? ReachEverywhere here, which markets the Shopper iPhone Shopping Assistant application, announced that it is integrating real-time recall information from the Food and Drug Administration and the U.S. Department of Agriculture into the application. Users of the application who put an item on their list that is associated...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 03 Dec 2009 16:19:56 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/application.html"><![CDATA[application]]></category>
		<category domain="http://resources.bnet.com/topic/information.html"><![CDATA[information]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+agriculture.html"><![CDATA[U.S. Department Of Agriculture]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Offers Pfizer's HIV Drug Selzentry New Life -- For All the Good It Will Do]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005550/fda-offers-pfizers-hiv-drug-selzentry-new-life-for-all-the-good-it-will-do/]]></link>
		<description><![CDATA[The FDA approved Pfizer's anti-HIV drug Selzentry for expanded use in combination with other antiretroviral agents for treatment-naÃ¯ve patients who are infected with only CCR5-tropic HIV-1. Contrary to company expectations, perceived limitations of this entry inhibitor could stall efforts to facilitate usage beyond salvage therapy. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 30 Nov 2009 10:57:52 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[AstraZeneca Moves Drug Production to China, Begging Safety Questions for FDA]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005527/astrazeneca-to-move-drug-production-to-china-trend-begs-safety-questions-for-fda/]]></link>
		<description><![CDATA[AstraZeneca AZN will move all its drug production to China. The move is part of a trend: Drug companies with massive Western operations are shutting them down and moving them to China. The unanswered question is, how will the FDA monitor production of drugs destined for the U.S. if all...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 27 Nov 2009 19:40:22 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/monitors+%2526+displays.html"><![CDATA[Monitors & Displays]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[Hardware]]></category>
		<category domain="http://resources.bnet.com/topic/components.html"><![CDATA[Components]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[Zicam Makers Strike Back]]></title>
		<link><![CDATA[http://moneywatch.bnet.com/saving-money/blog/devil-details/zicam-makers-strike-back/1056/]]></link>
		<description><![CDATA[The makers of Zicam cold remedies turned their battle with the Food and Drug Administration public this week, filing a 33-page letter with securities regulators that discloses details of its long-running dispute. Now Zicam's parent company, Matrixx Initiatives, is asking that the FDA provide information about why it banned the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 20 Nov 2009 08:57:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/maker.html"><![CDATA[Maker]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/kathy+kristof.html"><![CDATA[Kathy Kristof]]></category>
	</item>
	<item>
		<title><![CDATA[AstraZeneca files Brilinta NDA]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/astrazeneca-files-brilinta-nda/21115/]]></link>
		<description><![CDATA[ AstraZeneca today announced it has submitted an NDA to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome ACS. The proposed trade name for ticagrelor is Brilinta, pending approval from the FDA.  Release  ]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 19 Nov 2009 09:03:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/reduction.html"><![CDATA[reduction]]></category>
		<category domain="http://resources.bnet.com/topic/treatment.html"><![CDATA[treatment]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005372/a-cure-for-genzymes-pompe-disease-treatment-ceo-termeers-ouster/]]></link>
		<description><![CDATA[Genzyme announced that the FDA is delaying final approval of the company's application to market Lumizyme alglucosidase alfa for the treatment of Pompe disease. Not unexpected, given FDA regulators had sent out a memo last Friday warning healthcare providers that enzyme replacement drugs made at the Allston Landing plant might...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 19 Nov 2009 07:56:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="tickers">GENZ</category>
	</item>
	<item>
		<title><![CDATA[FDA Accused of Caving to Industry in Oyster Row]]></title>
		<link><![CDATA[http://industry.bnet.com/food/10001119/fda-accused-of-caving-to-industry-in-oyster-row/]]></link>
		<description><![CDATA[Under President Barack Obama, the Food and Drug Administration has showed some backbone for the first time in years. But now it's backtracking on the issue of raw oysters from the Gulf Coast, thrilling industry but disappointing health advocates.    The FDA had announced new rules, effective 2011,...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 17 Nov 2009 10:00:32 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/industry.html"><![CDATA[Industry]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/katherine+glover.html"><![CDATA[Katherine Glover]]></category>
	</item>
	<item>
		<title><![CDATA[FDA: Watch out for tainted Genzyme drugs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/fda-watch-tainted-genzyme-drugs/20498/]]></link>
		<description><![CDATA[Genzyme just can't seem to catch a break. Vials of five of its meds for rare diseases may be tainted with bits of rubber, steel, or foreign fibers, the FDA said. And while the contamination doesn't seem to be widespread, it does raise more questions about quality control at the...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Mon, 16 Nov 2009 08:36:13 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/contamination.html"><![CDATA[Contamination]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="tickers">GENZ</category>
	</item>
	<item>
		<title><![CDATA[FDA tackles gray area of social media]]></title>
		<link><![CDATA[http://industry.bnet.com/technology/news-analysis/fda-tackles-gray-social-media/20355/]]></link>
		<description><![CDATA[By Deepa Seetharaman WASHINGTON (<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>)- Drug makers, Internet companies and nonprofits called for clarity on what is a gray area for U.S. health regulators: how drug promotion on Twitter, Wikipedia, blogs and other social media can be regulated. The two-day Food and Drug Administration hearing aims to find out if...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 13 Nov 2009 13:34:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/twitter+inc..html"><![CDATA[Twitter Inc.]]></category>
	</item>
	<item>
		<title><![CDATA[FTC Eyes Supply Dispute Between Drugmakers]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/ftc-eyes-supply-dispute-drugmakers/20277/]]></link>
		<description><![CDATA[The Federal Trade Commission is concerned that some brand-name drugmakers are declining to supply some bulk ingredients to their generic rivals which, of course, want to use materials to make copies of more expensive meds, The Wall Street Journal writes. Meanwhile, GlaxoSmithKline cites a federal drug-safety program as its reason...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 13 Nov 2009 05:47:05 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/program.html"><![CDATA[program]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/ftc.html"><![CDATA[FTC]]></category>
		<category domain="http://resources.bnet.com/topic/teva+pharmaceuticals.html"><![CDATA[Teva Pharmaceuticals]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Seeks Advice From Blogger; Google Solves Pharma's Ad Problems]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005281/fda-seeks-advice-from-blogger-google-solves-pharmas-ad-problems/]]></link>
		<description><![CDATA[The FDA sought the advice of John Mack, a blogger with 20,000 monthly readers who runs the Pharma Marketing Blog, on how drug companies should use the web to advertise their products. The agency usually likes to hear from lawyers, drug company executives and academics when it seeks regulatory advice....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 15:08:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/advice.html"><![CDATA[Advice]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/blogger.html"><![CDATA[Blogger]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">GOOG</category>
	</item>
</channel>
</rss>
